Sitryx TherapeuticsImmunologySitryx adds another BigPharma and partners with Boehringer Ingelheim in autoimmune pushOxford-based immunology specialist Sitryx has entered into a new agreement with Boehringer Ingelheim aimed at advancing a novel small-molecule programme in autoimmune and inflammatory disease. The deal … more ➔
M&AJapan’s Asahi Kasei buys antiviral specialist Aicuris in €780 million dealTakeover in Wuppertal: Aicuris Anti-Infective Cures AG, which specializes in active ingredients for infectious diseases, is being acquired by Japanese pharmaceutical company Asahi Kasei for almost €800 … more ➔
Rare diseaseargenx expands VYVGART into ocular MG as profitability signals franchise maturityargenx delivered two significant updates on the same day: positive Phase 3 results in ocular myasthenia gravis (oMG) and its first full year of operating profitability. Together, the announcements show … more ➔
anti-obesityNovo Nordisk partners with MIT spinout Vivtex in deal worth up to $2.1bn to advance oral biologics for obesityDenmark’s Novo Nordisk has signed a collaboration with Boston-based Vivtex Corporation to develop next-generation oral biologic medicines for obesity, diabetes and associated metabolic diseases. Vivtex … more ➔
AcquisitionGSK buys 35Pharma for $950m, targeting next-generation pulmonary hypertension therapy and the TGF-β superfamilyGSK will pay $950m for Montreal-based 35Pharma to secure HS235, an investigational activin signalling inhibitor that has completed Phase I trials in healthy volunteers and is set to begin studies in … more ➔
BeiersdorfSkin careSkin in the AI game: Beiersdorf Ventures invests in AI biology platform TurbineAs a co-investor in the USD 25 million Series B round, Beiersdorf AG is signalling that artificial intelligence is becoming strategically important for skin research. The Hamburg-based group is participating … more ➔
BrainomixAIBrainomix extends Series C to £18.8m as Oxford AI imaging spinout pushes into the USOxford-based Brainomix has added £4.8 million (approximately $6.5m/€5.5m) to its Series C financing, bringing the total round to £18.8 million ($25.4m/€21.5m) and providing fresh capital to accelerate … more ➔
BioNTech SECancer vaccinationEarly BioNTech mRNA breast cancer trial delivers surprise in longtime disease controlA study recently published in Nature on the use of mRNA “vaccines” targeting cancer neoantigens in triple-negative breast cancer (TNBC) has generated considerable attention in scientific circles. … more ➔
CollaborationAngelini partners with Quiver on AI-driven discovery in genetic epilepsiesItaly’s Angelini Pharma has signed a multi-year research collaboration and licensing agreement with Massachusetts-based Quiver Bioscience to discover new treatments for genetic epilepsies, including … more ➔
Flu vaccinesEurope accelerates next-generation flu vaccines with €225m innovation procurement pushA group of vaccine developers, biotech firms and public health institutes, including Bavarian Nordic and Sanofi, has secured framework contracts under a €225 million EU initiative to accelerate the … more ➔
Sitryx Therapeutics
Beiersdorf
Brainomix
BioNTech SE
